Novo Nordisk reported positive Phase III FRONTIER4 data showing sustained safety and low bleeding rates with investigational denecimig in hemophilia A, while Phase III explorer10 results showed concizumab reduced annualized bleeding rates by 82% in children with hemophilia and inhibitors.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
Novo Nordisk has reported new Phase III data supporting the long-term safety and efficacy of investigational denecimig (Mim8) for hemophilia A and presented new pediatric findings for concizumab during the International Society on Thrombosis and Haemostasis (ISTH) Congress 2026 in Paris. The results strengthen the company’s hemophilia pipeline as denecimig remains under US Food and Drug Administration (FDA) review through a Biologics License Application (BLA) submitted in September 2025.
Denecimig is an investigational subcutaneous factor VIIIa (FVIIIa)-mimetic bispecific antibody developed for routine prophylaxis in children, adolescents, and adults with hemophilia A, regardless of inhibitor status. By bridging activated factor IX and factor X, the antibody mimics the activity of factor VIIIa and restores thrombin generation, reducing the risk of spontaneous bleeding. Hemophilia A is an inherited bleeding disorder caused by deficiency or dysfunction of factor VIII, and treatment becomes more challenging in patients who develop inhibitors against replacement therapy.
Phase III FRONTIER4 Results
The interim analysis of the ongoing open-label Phase III FRONTIER4 extension study (NCT05685238) included 426 participants aged one year and older receiving denecimig prophylaxis. The analysis evaluated once-weekly, every-two-week, and once-monthly dosing schedules following participation in earlier FRONTIER studies.
The primary safety endpoint showed a profile consistent with previous studies. Injection-site reactions occurred in only 2.0% of injections in children and 1.8% in adolescents and adults, with all events reported as mild and transient. Investigators observed no clinical evidence of neutralizing antibodies.
Efficacy remained consistent across dosing regimens and inhibitor status. Estimated mean annualized bleeding rates (ABRs) were 0.75 (95% CI, 0.60-0.93) in adults and adolescents and 0.37 (95% CI, 0.17-0.76) in children. Approximately 71% of adults and adolescents and 89% of children experienced no treated bleeding episodes during denecimig prophylaxis. Patient-reported outcomes also showed sustained improvements in joint pain, reduced treatment burden, and high satisfaction with the pen injector across all dosing schedules.
Additional post hoc analyses from the Phase III FRONTIER2 (NCT05053139) and FRONTIER5 studies (NCT05878938) found that denecimig increased thrombin generation into the normal reference range in adolescents and adults without evidence of excessive coagulation, further supporting its proposed mechanism of action.
Concizumab Shows Benefit in Children
Novo Nordisk also presented the first Phase III explorer10 results evaluating concizumab prophylaxis in 24 children younger than 12 years with hemophilia A or B and inhibitors. Compared with previous on-demand treatment, concizumab reduced the estimated mean annualized bleeding rate from 11.51 to 2.08, representing an 82% reduction (ABR ratio 0.18; 95% CI, 0.11-0.29).
Most treatment-emergent adverse events were mild, injection-site reactions were uncommon, and 29% of participants experienced serious adverse events. Concizumab is currently approved in several regions for adolescents and adults but remains investigational in children younger than 12 years.
Executive Perspective
Martin Holst Lange, MD, Executive Vice President and Chief Scientific Officer at Novo Nordisk, said the FRONTIER4 findings reinforce denecimig’s potential to provide flexible prophylactic treatment across age groups, inhibitor status, and dosing schedules.
Guy Young, MD, Director of the Hemostasis and Thrombosis Center at Children’s Hospital Los Angeles, noted that long-term safety data and dosing flexibility are important considerations for lifelong hemophilia management and suggested the results could expand treatment options for a broad patient population.
Path Froward
The new data support Novo Nordisk’s regulatory submission for denecimig in the United States and add to the growing evidence from the Phase III FRONTIER clinical program. Continued follow-up from FRONTIER4 and the ongoing explorer10 study will further define the long-term role of denecimig and concizumab in hemophilia care.
What This Means for Patients
The new Phase III data suggest that denecimig could provide people with hemophilia A with effective long-term bleed prevention through flexible dosing schedules ranging from once weekly to once monthly, while maintaining a favorable safety profile. In addition, concizumab showed a substantial reduction in bleeding episodes in children with hemophilia A or B and inhibitors, supporting its potential to expand preventive treatment options for younger patients if approved.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.